Jaeschke, Georg

Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice

Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 489

Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 308

CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor

Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 118

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion

Tian, D., Stoppel, L. J., Heynen, A. J., Lindemann, L., Jaeschke, G., Mills, A. A., & Bear, M. F. (2015) · Nature Neuroscience

Genetics and Neurodevelopmental DisordersGenomic variations and chromosomal abnormalities

Cited by 109

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 107

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 106

Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice

Michalon, A., Bruns, A., Risterucci, C., Honer, M., Ballard, T. M., Ozmen, L., Jaeschke, G., Wettstein, J. G., von Kienlin, M., Künnecke, B., et al. (2014) · Biological Psychiatry

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 67

Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 66